In-vitro, CCL24 induced the migration and myofibroblast-differentiation of dermal fibroblasts [121], and blockade of CCL24 reduced EC activation by SSc sera, EC angiogenesis, and prevented in-vitro-induced EndMT [97,121,124]. Here, CCL24 is linked to systemic sclerosis.